These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28671424)

  • 1. Nonalcoholic Fatty Liver Disease: Identifying Patients at Risk of Inflammation or Fibrosis.
    Osayande AS; Kale N
    Am Fam Physician; 2017 Jun; 95(12):796-797. PubMed ID: 28671424
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
    Tsai E; Lee TP
    Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease.
    Patel V; Sanyal AJ; Sterling R
    Clin Liver Dis; 2016 May; 20(2):277-92. PubMed ID: 27063269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter to the editor: diagnosing fibrosis and cirrhosis in nonalcoholic fatty liver disease using machine learning models.
    Feng Y; Peng B; Li Y; Sun L; Sun Y
    Hepatology; 2023 May; 77(5):E103-E104. PubMed ID: 36645222
    [No Abstract]   [Full Text] [Related]  

  • 5. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
    Stål P
    World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New guidelines for NAFLD – a Swedish perspective].
    Hagström H; Hoffstedt J; Reynisdottir S
    Lakartidningen; 2017 Feb; 114():. PubMed ID: 28221405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
    Kaswala DH; Lai M; Afdhal NH
    Dig Dis Sci; 2016 May; 61(5):1356-64. PubMed ID: 27017224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
    World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyperhomocysteinemia--a predictor of inflammatory changes in the liver].
    Zviagintseva TD; Hlushchenko SV
    Lik Sprava; 2014 Nov; (11):154-5. PubMed ID: 25528857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease.
    Castera L
    Semin Liver Dis; 2015 Aug; 35(3):291-303. PubMed ID: 26378645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
    Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
    Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of nonalcoholic fatty liver disease (NAFLD).
    Yki-Järvinen H
    Duodecim; 2016; 132(22):2099-106. PubMed ID: 29190058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of Cardiovascular Events and Effect on Survival in Liver Transplant Recipients for Cirrhosis Due to Alcoholic or Nonalcoholic Steatohepatitis.
    Piazza NA; Singal AK
    Exp Clin Transplant; 2016 Feb; 14(1):79-85. PubMed ID: 26581602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.
    Li Q; Lu C; Li W; Huang Y; Chen L
    Oncotarget; 2017 Apr; 8(17):28641-28649. PubMed ID: 28415736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.
    Diehl AM; Day C
    N Engl J Med; 2017 Nov; 377(21):2063-2072. PubMed ID: 29166236
    [No Abstract]   [Full Text] [Related]  

  • 19. How to Approach a Patient With Nonalcoholic Fatty Liver Disease.
    Tilg H
    Gastroenterology; 2017 Aug; 153(2):345-349. PubMed ID: 28647352
    [No Abstract]   [Full Text] [Related]  

  • 20.  Estimated time from clinical presentation to the development of cirrhosis in non-cirrhotic adult patients with non-alcoholic fatty liver disease.
    Minuk GY; Sanders J; O'Brien M; Uhanova J
    Ann Hepatol; 2016 Nov-Dec 2016; 15(6):944-945. PubMed ID: 27740531
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.